bpc 157 human evidence clinical trials safety Multifunctionality and Possible Medical Application of the Peptide—Literature and Patent Review BPC-157: Experimental Peptide Creates Risk
Description
Risk of herpes/herpes zoster during anti- tumor necrosis factor therapy in patients with rheumatoid arthritis
While the results were not as impressive when studied in a double-blind fashion (compared to the earlier unblinded studies), the blinded studies, nevertheless, confirmed that about 2/3 to 3/4 of treated cases improved, and that at least 50% of the patients had a reduction of spasticity by more than 20% [138, 139, 141]
PMC 7319989
S2CID 28549709
